Meloxicam Recall: Silintan 25 pills (25-count bottle)
Announced 2026-03-11 · FDA
The FDA recalls Silintan 25 pills due to the presence of undeclared meloxicam and marketing without an approved NDA/ANDA. The recall includes all lots within expiry and was distributed nationwide in the United States.
| Brand | ANTHONY TRINH, 123Herbals LLC |
|---|---|
| Product | SILINTAN 25/pills, packaged in a 25-count bottle, Shanghai Chinese Medical Works, Shanghai, China |
| Reason | Marketed Without an Approved NDA/ANDA: FDA analysis revealed the presence of undeclared meloxicam. |
| Severity | critical |
| Units affected | N/A |
| Distribution | USA nationwide |
| Agency | FDA |
WHAT YOU SHOULD DO
- If you have Silintan 25 pills, stop using them immediately and do not consume any remaining tablets.
- Follow FDA recall instructions for disposal or return of the product and contact the retailer or manufacturer for guidance.
- If you have experienced adverse health effects, seek medical care and report them to your healthcare provider and to FDA MedWatch.
How to identify the recalled item
| Lot / date codes | All lots within expiry |
|---|---|
| Lot / date codes | All lots within expiry |
These are the identifiers FDA published for this recall. Most recall notices list no UPC or model number at all — if the code on your item is not shown here, that does not mean the item is excluded. Check the official notice, or contact the company.
This is an automatically maintained record of an official recall notice. Details can change; always follow the official notice linked above. See all records in the Recall Database.